The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.
A total of 410 patients with blast phase myeloproliferative neoplasm (MPN-BP) were retrospectively reviewed: 248 from Mayo Clinic and 162 from Italy. The median survival was 3.6 months, with no improvement over the last 15 years. Multivariable analysis performed on the Mayo cohort identified high-risk karyotype, platelet count, and transfusion need as independent risk factors for survival. Also in the Mayo cohort, intensive chemotherapy resulted in complete remission or complete remission with incomplete count recovery rates of 35% and 24%, respectively; treatment-specified 3-year/5-year survival rates were 32%/10% for patients receiving allogeneic stem-cell transplant, 19%/13% for patients achieving complete remission or complete remission with incomplete but were not transplanted, and 1%/1% in the absence of both allogeneic stem-cell transplant and complete remission or complete remission with incomplete. Similar observations were made in the Italian cohort. The current study identifies the setting for improved short-term survival in myeloproliferative neoplasm but also highlights the limited value of current therapy, including allogeneic stem-cell transplant, in securing long-term survival. The study was published in Leukemia.